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Anaphylaxis in humans is inherently difficult to study due to the acuteness of symptoms 
and the lack of biomarkers serving as risk predictors. Most cases are related to IgE 
sensitizations to foods, insect venoms, and drugs with mastocytosis patients forming 
a smaller risk group. However, identifying the relatively small fraction of persons at risk 
has been exceedingly difficult. In this review, we propose to describe anaphylaxis in a 
broader context than defined by IgE sensitization alone. Exposure to a trigger, such as 
an allergen, may lead to anaphylaxis, but in particular, the internal dose sensed by the 
immune system needs to be established. Moreover, intrinsic patient factors as well as the 
specific circumstances of the exposure, i.e., the extrinsic factors, need to be thoroughly 
accounted for. More controversially, other triggers of anaphylaxis, such as increased 
sensitivity to or reduced catabolism of histamine (“histamine intolerance”) or mast cell 
activation syndrome also named mast cell activation disorder have been suggested, 
but still with very limited epidemiological evidence that a significant proportion of the 
observed reactions are caused by these alleged conditions. Thus, when all conditions 
are considered, it seems as if IgE-mediated reactions are responsible for the vast majority 
of anaphylactic conditions.
Keywords: anaphylaxis, allergens, mast cells, mast cell activation, cofactors
inTRODUCTiOn
Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death (1). It typi-
cally involves one or more of the symptoms: an itchy rash, throat or tongue swelling, shortness of 
breath, vomiting, lightheadedness, and low blood pressure (BP) appearing in minutes to hours after 
a stimulus that is mostly believed to be of exogenous origin.
Epidemiological studies are scarce (1), but recent studies suggest that foods (two-thirds), insect 
venoms (20%), and drugs are among the most frequent triggers, with differences between age groups. 
A special population at risk seems to be patients with mastocytosis, where various triggers including 
mechanical stimuli and insect stings—even without the presence of allergic sensitizations to venom 
allergens—may precipitate severe reactions.
While becoming increasingly popular in quasi-scientific fora on the Internet, other triggers 
of anaphylaxis, such as increased sensitivity to or reduced catabolism of histamine (“histamine 
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tolerance”) or mast cell activation syndrome (MCAS) also 
named mast cell activation disorder (MCAD) still have unclear 
definitions and limited epidemiological evidence exists that a 
significant proportion of anaphylaxis should be caused by these 
alleged conditions. Thus, when all conditions are considered, it 
seems as if IgE-mediated reactions are responsible for the vast 
majority of anaphylactic conditions.
When looking at the triggers of anaphylaxis, it is clear, 
however, that only a tiny fraction of patients with food, insect 
venom, or drug allergy will experience an anaphylactic reaction. 
Due to the severity and life-threatening nature of anaphylactic 
reactions, it is of utmost importance to identify the risk factors 
in these patients that may predict—or ultimately prevent—the 
occurrence of anaphylactic reactions. While some foods seem 
to be more allergenic than others, there is little prognostic value 
in both food sources and sensitization to specific allergens. 
A similar uncharacteristic pattern has emerged for insect venoms, 
and even more so for drugs where the diversity and complexity 
of drugs make it impossible to gather much experience except for 
large drug groups such as beta lactam antibiotics.
Next in line for the risk analysis comes quantitative factors, 
such as the IgE-titer—or more indirectly: skin test response—to 
certain allergens. Also, these parameters have, however, failed to 
be strongly predictive of anaphylaxis risk, and examples can be 
found where the IgE-titer in serum over time has fallen below the 
detection limit, while the patient has retained clinicial reactivity 
upon reexposure (2). While IgE sensitization is still the best bio-
marker for risk of anaphylaxis, we aim at identifying additional 
features of the anaphylaxis pathophysiology that may eventually 
provide tools for identifying the patients at high risk.
All the above evidence suggests that individual factors to a 
great extent determine the severity of the allergic response and 
thereby also the risk of developing anaphylaxis, but knowledge 
about predictive factors is lacking. In this paper, we propose 
a theoretical framework for the pathogenesis of anaphylaxis, 
which by investigating a putative pathway of the mast cell activa-
tion, the primary target cells of the mast cell mediators, and of 
the neurological and other secondary mechanisms in the vascu-
lature display a research paradigm that may help shedding some 
light on a disease, which by its acute form and unpredictable 
occurrence has so far eluded a more systematic study approach 
(Figure 1A).
TYPe 1 HYPeRSenSiTiviTY
The hypersensitivity reaction classified by the British immuno-
logists, Philip Gell and Robin Coombs, as the type 1 reaction (now 
also named the IgE-mediated allergic reaction, but notably IgE 
had still not been discovered and named in 1963, when Gell and 
Coombs first suggested their classification of this humoral form 
of hypersensitivity), still provides the basic theoretical framework 
for our discussion of anaphylaxis. Centrally in this theory is the 
involvement of effector cell-bound antibodies, which upon bind-
ing to an allergen will induce activation and release of anaphy-
lactogenic mediators. Immunoglobulin E is in humans the only 
antibody class with a solid evidence of binding to and activating 
the effector cells, mast cells, and basophil granulocytes, via the 
tetrameric form of the high affinity IgE receptor, the FcεRI com-
prising one alpha, one beta, and two gamma units (as opposed to 
the trimeric form of the receptor, lacking the beta-chain, which 
may be found on other cell types not believed to take part in the 
acute allergic reaction). So-called homocytotrophic antibodies, 
i.e., antibodies binding to effector cells, of other isoforms such 
as IgG4 (3), IgD (4), and even isolated light chains (5) have been 
suggested, but not supported by a solid body of evidence. There 
is likely to be marked differences between man and rodents, and 
while the human isotype IgG4 has similarities to mouse, rat, and 
guinea pig IgG1, there is little evidence of functional effector cell 
receptors playing an important clinical role in the human system. 
Thus, it seems fair to conclude that most anaphylactogens are in 
fact allergens, as defined as an antigen to which an IgE-immune 
response is mounted.
As mentioned above, there is a large body of literature dis-
cussing the quality and quantity of IgE, in relation to anaphylaxis 
caused by foods, insect venoms, and drugs. Many such studies 
suggest that not all allergens may necessarily be anaphylactogens, 
but since our aim is to go beyond this discussion, we will not dwell 
further on this aspect, but refer the reader to the vast amount of 
literature most recently reviewed in Ref. (6).
ALLeRGOKineTiCS AnD inTeRnAL DOSe
Much less studied are the pathways before and after the sen-
sitized effector cell meets the allergen (Figure  1A). We have 
used the term allergokinetics (derived from the terms and 
concepts of pharmacokinetics and toxicokinetics) to describe 
the mechanisms by which an allergen source such as a food, an 
insect venom, or a drug is taken up by the body, how the aller-
genic (=IgE-binding) molecules are solubilized, absorbed over 
biological membranes, and eventually distributed in the organ-
ism where it is able to meet and activate effector cells, causing 
mediator release. Even less studied are the subsequent events 
where the allergen is potentially metabolized and excreted by the 
organism.
We propose to use the concept of internal dose, to describe the 
quantity of the anaphylactic trigger (most often an allergen) that 
becomes available to the systemic circulation, from where it is 
believed to activate the vascular system.
Old studies using the method of passively sensitizing heal-
thy persons with a hyperimmune serum from a sensitized 
person, followed by ingestion of the culprit allergenic food, has 
demonstrated a much faster uptake than would be expected by 
normal gastrointestinal physiology (7). This was confirmed by 
studies using sensitive biological tests (8, 9) for detection of 
allergen in plasma of non-allergic persons ingesting foods to 
which hyperimmune sera could be used for detection. Finally, 
an elegant revival of the old Prausnitz–Küstner method has 
been used after a rigorous ascertainment of the safety of the 
sensitizing serum. Here, an inverse relationship between oral 
dose and onset of skin reaction was demonstrated (10). The 
overall conclusions from these studies suggest that less than 
one part per million of food protein (and thus almost out of 
reach with the present status of analytical allergen detection) 
is absorbed systemically. However, so far, it has not been 
FiGURe 1 | (A) A theoretical outline of the pathogenesis of anaphylaxis induced by a single trigger. After absorption and redistribution, the trigger reaches and 
activates the effectors cells. The ensuing mediator release induces the primary target cells to react, which may in turn activate compensatory or enhancing 
mechanisms. (B) A theoretical outline of the pathogenesis of anaphylaxis induced by a single trigger, but modified by host-specific intrinsic and extrinsic factors. The 
modifying factors may alter each of the steps: cellular activation, primary target cell activation, or secondary cellular or tissues activation.
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possible to study whether similar mechanisms of limited intact 
food allergen absorption is taking place in allergic patients, or 
whether they might have qualitatively different mechanisms 
operating.
Some foods are known to potentially induce severe anaphy-
lactic reactions, such as egg and milk in early childhood, and 
peanut, tree nuts, fish, and shellfish persistently throughout life. 
It is well-accepted that a “dangerous” food contains allergens that 
are sufficiently resistant to gastrointestinal proteolysis allowing 
them to cross the gut epithelial barrier and cause systemic reac-
tions. Legume and tree nut storage proteins such as peanut Ara 
h 2 and lipid transfer proteins such as peach Pru p 3 are probably 
the best characterized molecules in this category. They are both 
highly resistant to proteolysis and have been identified as risk 
factors for severe symptoms. Nevertheless, a very significant 
number of patients sensitized to such stable allergens only expe-
rience mild symptoms, usually limited to the oral cavity. This 
means that, besides protease-resistance, other factors determine 
the clinical outcome of exposure to potentially severe (stable) 
allergens.
The relationship between the internal dose reaching the 
immune system, and the actual dose administered via ingestion, 
inhalation, skin absorption, or via parenteral routes is not only 
determined by absorption. In particular, many food allergens are 
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digested in the stomach but may also react or become absorbed 
intact in the buccal mucosa (8). The clinical studies of threshold 
values to allergenic challenges suggest that there are large interin-
dividual (of 3–5 decades) differences between patients’ threshold 
dosages when challenged with food allergens. Although insuf-
ficient data are available, it seems most likely that each individual 
has his/her own threshold value, and the more the given dose 
exceeds this threshold, the higher likelihood of an anaphylactic 
reaction.
MeDiATOR ReLeASe AnD PRiMARY 
TARGeT CeLL ACTivATiOn
Following mediator cell activation, different mediators, the most 
prominent being histamine, but likely also involving tryptase, 
prostaglandins, the sulphido-leukotrienes, LTC4, LTD4, and 
LTE4; platelet aggregating factor and other lipid-derived media-
tors are released to the surrounding tissue to act locally and sys-
temically. Both primary triggers such as allergens and mediators 
released by these may be systemically distributed, but it is rarely 
clear which of the two distribution mechanisms that are most 
important for the systemic nature of anaphylaxis.
SeCOnDARY eFFeCTS: LOCALiZeD  
OR SYSTeMiC ReSPOnSe?
Anaphylaxis can affect multiple organ systems and results in 
a broad range of symptoms from the skin and mucous mem-
branes, upper and lower respiratory tract, gastrointestinal tract, 
and cardiovascular and nervous systems. Cutaneous symp-
toms are present in more than 80% of episodes and are often 
transient including erythema, pruritus, rash, and urticaria/
angioedema (11, 12). During skin and mucosal symptoms, the 
dermal microvasculature is highly unbalanced and important 
extravasations of fluid occurs. However, the vascular system 
extends well beyond of the microvasculature. The majority of 
severe alterations described in human anaphylaxis involve the 
vascular system and hypotension is one of three important cri-
teria for diagnosing anaphylaxis, with resulting hypoxia being a 
key feature contributing to the severity of the reaction (13, 14). 
Overall hemodynamic defects are fundamental for the sudden 
fall in the BP and may directly cause some of the neurologic 
symptoms as dizziness, fainting, and seizures associated to 
severe anaphylaxis. Moreover, involvement of the gastroin-
testinal system (abdominal pain, cramping, nausea, vomiting, 
incontinence, and diarrhea) has been strongly correlated with 
hypotension and hypoxia too. Low BP during anaphylaxis 
might result in decreased myocardial perfusion, which in turn 
causes arrhythmias and cardiovascular collapse. The respiratory 
system is commonly affected giving rise to symptoms such as 
dyspnea, wheezing, stridor, deep cough, upper airway obstruc-
tion, asphyxia, and respiratory arrest (15, 16).
The extravasation of fluid leads to decreased venous return, 
which in turn causes insufficient filling of the heart, reduced 
cardiac output, and ultimately cardiac arrest. Respiratory 
obstru ction/arrest, cardiovascular collapse, or a combination 
of these might be fatal. Moreover, there is increasing evidence 
of the human heart as a target of cardiac anaphylaxis involving 
human heart mast cells (17), but this area deserves further 
studies.
PATienT-ASSOCiATeD inTRinSiC 
FACTORS
Clearly, allergen dose and the patients IgE titer are not enough to 
predict the severity of an anaphylactic reaction, and other con-
tributing factors termed cofactors may be described as intrinsic 
or extrinsic (Figure 1B).
Patients with, e.g., severe food allergy often report an almost 
immediate tingling sensation in the mouth, already upon expo-
sure to tiny quantities of the offending food. An anaphylactic 
reaction can occur within a few minutes, so symptoms are initi-
ated long before the food allergen has had the chance to pass the 
stomach into the intestinal tract and interact with the relevant 
epithelial mast cells. This suggests that the process of anaphylaxis 
already starts when the allergen is exposed to the oral (or esopha-
geal) mucosal/epithelial barrier. The kinetics of uptake of food 
proteins over the oral mucosal barrier is a poorly understood 
process that may differ between patients with mild and severe 
food allergy. Anaphylactic patients may have a more permeable 
mucosal/epithelial barrier in the oral cavity but possibly also in 
the intestinal tract. In addition to differences in the physical bar-
rier function, the innate immune function of epithelial cells may 
also differ, and the number of subepithelial tissue mast cells and/
or their sensitivity to allergen may distinguish between patients 
with mild and severe reactions. Also, differences in the phenotype 
and thus responsiveness of mast cells (18) and basophils (19) may 
play a role.
In addition, much more crude physiological parameters, such 
as age, hormonal status, and comorbidities may determine the 
reactivity of the organism being exposed to an anaphylactic trig-
ger, and it is important to emphasize that the intrinsic, as well 
as the extrinsic factors described below, may interact differently 
with each of the steps in the anaphylactic pathway.
eXTRinSiC FACTORS: FOOD, 
LiFeSTYLe, enviROnMenT,  
AnD inFeCTiOnS
Thresholds for allergic reactions to food also have considerable 
intraindividual variability. It is nevertheless assumed that all 
patients can develop severe reactions, given the right combination 
of factors and events and if the dose is high enough. Apart from 
the dose of a food, there is also the way it is consumed, i.e., pure 
unprocessed, processed, and/or as part of a composite food. The 
matrix in which a food allergen is presented to mucosal surfaces, 
both with respect to its composition and its way of processing, 
is an extrinsic factor that has significant impact on release and 
uptake of food allergens (Figure 1B).
Other extrinsic factors that may influence allergen uptake 
are exercise shortly after food consumption (exercise-induced 
anaphylaxis), alcohol-use, and the use of non-steroidal 
FiGURe 2 | A theoretical outline of the pathogenesis of anaphylaxis induced by different triggers, with potentially different pathways. See text for discussion.
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antiinflammatory drugs and antacids (20, 21). Exercise-induced 
anaphylaxis is most commonly but not exclusively associated 
with wheat allergy. All these extrinsic factors are thought to 
increase gut permeability or increase allergen solubility, thereby 
lowering the threshold for severe reactions. Quantitative data 
are, however, not available. Some of these extrinsic factors may 
very well synergize into the perfect storm of a “party challenge” 
(dinner including potential allergens, alcohol, dance, preven-
tive aspirin, antacid), of which the quantitative impact is of 
course even more complex. Stress and sleep deprivation are 
also on the list of extrinsic factors that increase the risk for 
severe reactions. Last but not least, infections such as com-
mon cold (rhinovirus) and flu (influenza virus) have been 
implicated to increases hyperresponsiveness and may thus 
lower thresholds or increase the severity of a reaction. As 
of yet, the effects attributed to most of these extrinsic fac-
tors have not yet been confirmed by clinical, prospective 
studies.
TRiGGeRS OF THe AnAPHYLACTiC 
ReACTiOn
After having discussed the potential host-modifying (intrinsic 
and extrinsic) factors (Figure  1B), we can move back to the 
actual triggers (Figure 2) of the reaction. Clearly, not all clinical 
cases of anaphylaxis may be fully explained and diagnosed, but 
as previously cited from the literature, food seems to be most 
important trigger, followed by insect venom stings and drugs, 
the latter also including allergic side effects of allergen-specific 
immunotherapy, and systemic reactions caused by diagnostic 
(iatrogenic) allergen challenges.
Food
By definition, the oral route is the only relevant exposure to 
foods, even though food proteins are known to elicit (and per-
haps sensitize) via inhalation or via dermal exposure. This does 
not preclude, however, that the primary sensitization to a food 
allergen has taken place via another administration route.
insect venoms
Insect stings often occur in body areas with thin skin or on 
mucous membranes that allow a rapid and relatively unhindered 
systemic absorption of the individual venom components. By 
nature, these are toxic in their own right, and even if the patients 
is not allergic, large local reactions may be seen.
Drugs
Anaphylactic reactions to drugs are divided into allergic reac-
tions (including IgE-mediated reactions) and non-allergic 
reactions, which may have several other mechanisms, such as 
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activation via the complement system or direct actions of a drug 
on receptors of the target cell, e.g., opioid drugs activating mast 
cells directly, or more recently, the suggestion that some drugs 
may directly activate the mast cell via the MRGPRX2 surface 
receptor (22).
In practice, it is important not to limit the scope to the active 
component in prescription drug. Excipients and additives 
such as, e.g., methylcelluloses or polyethylene glycols (23) may 
also have allergenic potential. In addition, chemicals used for 
disinfection or sterilization such as chlorhexidine and ethylene 
oxide may be important to consider. Also, many drugs have 
potent effects in their own right, and the differentiation between 
pharmacological effects, side effects, and allergic symptoms is 
important for reaching the correct diagnosis (24).
Within the realm of perioperative anaphylaxis and postsurgi-
cal recovery, the administration of blood products may also give 
rise to anaphylactic reactions, and here, two immune systems, 
the host’s and donor’s, may be on collision course with other 
mechanisms than IgE being involved. Such mechanisms includes 
an immune-complex-mediated (with possible complement-
system involve ment also including the contact system) reaction 
between anti-IgA auto-antibodies of IgA-deficient donors and 
IgA of the recipient (25).
endogenous Cellular Activation: 
Mastocytosis and Other Mast  
Cell-Related Disorders
Mastocytosis is a well-known cause of anaphylaxis (26), which 
can often be diagnosed via the signature KIT D816V mutation 
(27). Additionally, condition(s) described as MCAS or MCAD 
have been suggested, but it has been difficult to establish firm 
criteria for this or these conditions. One important step forward 
was the suggestion to first eliminate primary MCADs such as 
mastocytosis and secondary activation disorders such as allergic 
reactions and other conditions caused by receptor-mediated 
mast cell activation before considering MCAS. Further, strict 
criteria have been proposed including (a) symptoms from two 
or more organs; (b) response to anti-mediator therapy; and 
(c) evidence of increased mediator turnover (28). It seems 
fair to state that the clinical significance of such reactions are 
still controversial and very limited epidemiological evidence 
exists where the above-described criteria have rigorously been 
applied. Thus, when all conditions are considered, it seems as 
if IgE-mediated reactions followed by mastocytosis-related 
anaphylaxis are responsible for the vast majority of anaphylactic 
conditions.
exogenous Mediator intake and/or 
Reduced Catabolism, i.e., Histamine 
intolerance
Scombroid poisoning—an allergy-like intoxication after inges-
tion of fish or other foods with high histamine content due to 
microbial degradation—can be considered as an overdose of 
histamine. Intake of more than 50 mg histamine/100 g food is 
considered toxic, but intake of histamine 20 mg/100 g food has 
in some cases elicited symptoms. None of the symptoms are 
pathognomonic to histamine poisoning, and the only reliable 
way to diagnose this condition is to measure histamine content 
in the food (29, 30).
It is likely that sensitive individuals exists, who may react to 
lower dosages of histamine, either because of an increased sen-
sitivity at the receptor level or because of a reduced catabolism 
of histamine, which is mainly degraded by the enzyme, diamine 
oxidase [see p. 89 in Ref. (31)]. In principle, similar syndromes 
may exists for other mediators. A considerable literature is avail-
able, but the diagnosis, histamine intolerance, is controversial (32) 
and not always easily differentiated from extrinsic or intrinsic 
factors described above.
COnCLUSiOn
Experimental evidence, both clinically and at laboratory level, is 
needed to facilitate better understanding of the mechanisms by 
which severe reactions occur, but also to be able to quantify their 
impact on threshold doses. Severe, potentially life-threatening 
anaphylactic reactions have great impact on the quality of life 
of patients. They are the basis of the anxiety and fear common 
to these patients and their relatives. An important knowledge 
gap relevant to evidence-based risk management of anaphylaxis 
is our poor ability to predict whether, and if so when, patients 
will develop such severe systemic, potentially life-threatening 
reactions. Here biomarkers are essential, and biomarkers that are 
bedded in mechanisms of disease are more powerful than mark-
ers identified simply by association (33). On the other hand, the 
difficulties in performing clinical research on patients with acute 
but fast remitting symptoms may also have inspired the proposal 
of a number of controversial disease mechanisms.
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